2008 Clinical Practice Guidelines - Canadian Diabetes Association

2008 CLINICAL PRACTICE GUIDELINES
S138
retinopathy. Dev Ophthalmol. 2007;39:31-47.
34. Massin P, Girach A, Erginay A, et al. Optical coherence tomography:
a key to the future management of patients with diabetic
macular oedema. Acta Ophthalmol Scand. 2006;84:466-474.
35. Whited JD. Accuracy and reliability of teleophthalmology for
diagnosing diabetic retinopathy and macular edema: a review
of the literature. Diabetes Technol Ther. 2006;8:102-122.
36. Davis MD, Fisher MR, Gangnon RE, et al. Risk factors for
high-risk proliferative diabetic retinopathy and severe visual
loss: Early Treatment Diabetic Retinopathy Study report #18.
Invest Ophthalmol Vis Sci. 1998;39:233-252.
37. Klein BEK, Moss SE, Klein R. Effect of pregnancy on progression
of diabetic retinopathy. Diabetes Care. 1990;13:34-40.
38. Chew EY, Klein ML, Ferris FL III, et al. Association of elevated
serum lipid levels with retinal hard exudate in diabetic
retinopathy. Early Treatment Diabetic Retinopathy Study
(ETDRS) report 22. Arch Ophthalmol. 1996;114:1079-1084.
39. Qiao Q, Keinänen-Kiukaanniemi S, Läärä E. The relationship
between hemoglobin levels and diabetic retinopathy. J Clin
Epidemiol. 1997;50:153-158.
40. The Diabetes Control and Complications Trial Research
Group. Effect of pregnancy on microvascular complications in
the Diabetes Control and Complications Trial. Diabetes Care.
2000;23:1084-1091.
41. Chew EY, Mills JL, Metzger BE, et al. Metabolic control and
progression of retinopathy. The Diabetes in Early Pregnancy
Study. Diabetes Care. 1995;18:631-637.
42. The Diabetes Control and Complications Trial Research
Group. The effect of intensive treatment of diabetes on the
development and progression of long-term complications in
insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:
977-986.
43. The Diabetes Control and Complications Trial Research
Group. The effect of intensive diabetes treatment on the progression
of diabetic retinopathy in insulin-dependent diabetes
mellitus. Arch Ophthalmol. 1995;113:36-51.
44. The Diabetes Control and Complications Trial Research
Group. Early worsening of diabetic retinopathy in the Diabetes
Control and Complications Trial. Arch Ophthalmol. 1998;116:
874-886.
45. UK Prospective Diabetes Study (UKPDS) Group. Intensive
blood-glucose control with sulphonylureas or insulin compared
with conventional treatment and risk of complications in
patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:
837-853.
46. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy
prevents the progression of diabetic microvascular complications
in Japanese patients with non-insulin-dependent
diabetes mellitus: a randomized prospective 6-year study.
Diabetes Res Clin Pract. 1995;28:103-117.
47. Klein R, Klein BEK, Moss SE, et al. Relationship of hyperglycemia
to the long-term incidence and progression of diabetic
retinopathy. Arch Intern Med. 1994;154:2169-2178.
48. Sivagnanam G. Rosiglitazone and macular edema. CMAJ.
2006;175:276.
49. Kendall C,Wooltoroton E. Rosiglitazone (Avandia) and macular
edema. CMAJ. 2006;174:623.
50. Klein R, Klein BEK, Moss SE, et al. The Wisconsin
Epidemiologic Study of Diabetic Retinopathy. XV.The long-term
incidence of macular edema. Ophthalmology. 1995;102:7-16.
51. Moss SE, Klein R, Klein BEK.Ten-year incidence of visual loss
in a diabetic population. Ophthalmology. 1994;101:1061-1070.
52. UK Prospective Diabetes Study Group. Tight blood pressure
control and risk of macrovascular and microvascular complications
in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
53. Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive
blood pressure control in normotensive type 2 diabetic
patients on albuminuria, retinopathy and strokes. Kidney Int.
2002;61:1086-1097.
54. Miljanovic B, Glynn RJ, Nathan DM, et al.A prospective study
of serum lipids and risk of diabetic macular edema in type 1
diabetes. Diabetes. 2004;53:2883-2892.
55. Fonda GE. Optical treatment of residual vision in diabetic
retinopathy. Ophthalmology. 1994;101:84-88.
56. Bernbaum M, Albert SG. Referring patients with diabetes and
vision loss for rehabilitation: who is responsible? Diabetes Care.
1996;19:175-177.
57. Chew EY, Ferris FL III, Csaky KG, et al.The long-term effects
of laser photocoagulation treatment in patients with diabetic
retinopathy: the Early Treatment Diabetic Retinopathy Followup
Study. Ophthalmology. 2003;110:1683-1689.
58. The Diabetic Retinopathy Vitrectomy Study Research Group.
Early vitrectomy for severe vitreous hemorrhage in diabetic
retinopathy. Four-year results of a randomized trial: Diabetic
Retinopathy Study report 5. Arch Ophthalmol. 1990;108:958-
964.
59. The Diabetic Retinopathy Vitrectomy Study Research Group.
Early vitrectomy for severe proliferative diabetic retinopathy in
eyes with useful vision. Results of a randomized trial—Diabetic
Retinopathy Vitrectomy Study report 3. Ophthalmology.
1988;95:1307-1320.
60. Smiddy WE, Flynn HW.Vitrectomy in the management of diabetic
retinopathy. Surv Ophthalmol. 1999;43:491-507.
61. Stolba U, Binder S, Gruber D, et al.Vitrectomy for persistent
diffuse macular edema. Am J Ophthalmol. 2005;140:295-301.
62. Chew EY, Klein ML, Murphy RP, et al. Effects of aspirin on
vitreous/preretinal hemorrhage in patients with diabetes mellitus.
Early Treatment Diabetic Retinopathy Study report no.
20. Arch Ophthalmol. 1995;113:52-55.
63. Early Treatment Diabetic Retinopathy Study Research Group.
Effects of aspirin treatment on diabetic retinopathy. ETDRS
report number 8. Ophthalmology. 1991;98(5 suppl):757-765.
64. Chew EY, Benson WE, Remaley NA, et al. Results after lens
extraction in patients with diabetic retinopathy: Early
Treatment Diabetic Retinopathy Study report number 25. Arch
Ophthalmol. 1999;117:1600-1606.
65. Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II
randomized double-masked trial of pegaptanib, an anti-